Viralytics to Present CAVATAK™ Clinical Data at American Association for Cancer Research Annual Meeting 2015

18 March 2015, Sydney, Australia: Viralytics Limited (ASX: VLA, OTC: VRACY) today announced that two Abstracts have been accepted for presentation at the American Association for Cancer Research (AACR) Annual Meeting 2015, April 18 to 22, in Philadelphia, PA. The Abstracts will be made available on the Meeting website tomorrow morning Australian time, details below. The full posters will be available from the date of the presentation, details also below.

The poster presentations will provide updated data from the ongoing Phase 2 CALM and Phase 1/2 STORM clinical trials of Viralytics’ lead drug candidate, CAVATAK™. CAVATAK is a novel cancer immunotherapy based on a proprietary cold virus that has been shown to preferentially infect and attack cancer cells.

Poster Presentation

- **Phase II CALM study: Changes in the tumor micro-environment induced by the immunotherapeutic agent, Coxsackievirus A21, delivered intratumorally in patients with advanced melanoma** (Abstract 7611)
  - Presenter: Dr Robert Andtbacka, Associate Professor at the University of Utah-based Huntsman Cancer Institute and Lead Study Investigator for the CALM trial
  - Poster Session: Clinical Trials in Progress
  - Monday, April 20, 2015, 8:00 AM – 12 noon
  - Location: Poster Section 25

Poster Presentation

- **Intravenous delivery of a novel oncolytic immunotherapy agent, CAVATAK, in advanced cancer patients** (Abstract 3483)
  - Presenter: Professor Hardev Pandha, The University of Surrey, and Principal Investigator of the STORM study.
  - Poster Session: Clinical Trials in Progress
  - Monday, April 20, 2015, 8:00 AM – 12 noon
  - Location: Poster Section 25

Abstracts of the two posters will be available on the AACR website at 1pm Eastern US time on March 18 (4am Sydney time on March 19):

American Association for Cancer Research (AACR) Annual Meeting 2015 - Abstracts
The abstracts can also be located from the Viralytics website.

The full poster presentations will be available from 20 April, 2015 US time, and a link will be provided on the Viralytics website.

About Viralytics Ltd:

Viralytics is developing oncolytic immunotherapy treatments for a range of cancers. Viralytics’ lead investigational product, CAVATAK™, is a proprietary formulation of the common cold Coxsackievirus Type A21 (CVA21). CVA21 binds to specific ‘receptor’ proteins highly expressed on multiple cancer types including, but not limited to: melanoma; prostate, lung, breast and bladder cancers; and multiple myeloma. CAVATAK™ acts to kill both local and metastatic cancer cells through cell lysis and the potential generation of an immune response against the cancer cells. Together this mechanism of action is known as oncolytic immunotherapy. CAVATAK’s preferential targeting of cancer cells creates the potential for a more tolerable cancer treatment.

The company has a number of clinical trials in progress, including:

- A Phase 2 clinical trial of intratumourally administered CAVATAK in the treatment of Late-Stage Melanoma (the CALM study), underway in the U.S.
- An extension to the CALM study focused on a deeper understanding of the immunotherapeutic activity of CAVATAK
- A Phase 1/2 clinical trial of intravenously delivered CAVATAK in patients with melanoma, prostate, lung or metastatic bladder cancers, referred to as the STORM (Systemic Treatment of Resistant Malignancies) study, underway in the UK
- A Phase 1 clinical trial of CAVATAK in bladder cancer, known as the CANON (CAVATAK for treatment of NON-muscle invasive bladder cancer) study, underway in the UK
- A Phase 1b clinical trial of CAVATAK in combination with YERVOY® (ipilimumab) in late-stage melanoma patients, forecast to enrol the first patient in Q1 2015.

Based in Sydney Australia, the company is listed on the Australian Securities Exchange (ASX: VLA) while Viralytics’ ADRs also trade under VRACY on the US OTCQX International market. For more information, please visit www.viralytics.com.

Enquiries:
Dr Malcolm McColl  Mr Rudi Michelson
Chief Executive Officer  Monsoon Communications
02 9988 4000  03 9620 3333